Tofacitinib: An Option for Acute Severe Ulcerative Colitis?
Tofacitinib has emerged as a new option for ulcerative colitis. Its rapid absorption, metabolism, and clinical improvement make it an interesting option for rescue therapy in acute severe ulcerative colitis (ASUC), a situation with limited therapeutic options in patients with a long-term disease course and multiple drug failure. The management of ASUC in this setting becomes challenging, underlying the need for new drugs and data on their efficacy and safety. We describe 2 cases of acute episodes in which tofacitinib was used as a rescue therapy.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Tofacitinib: An Option for Acute Severe Ulcerative Colitis? ; volume:29 ; number:2 ; year:2021 ; pages:132-134 ; extent:3
Portuguese journal of gastroenterology ; 29, Heft 2 (2021), 132-134 (gesamt 3)
- Creator
-
Santos, Sara
Gamelas, Verónica
Saraiva, Rita
Simões, Guilherme
Saiote, Joana
Ramos, Jaime
- DOI
-
10.1159/000514781
- URN
-
urn:nbn:de:101:1-2022032323173241099434
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Santos, Sara
- Gamelas, Verónica
- Saraiva, Rita
- Simões, Guilherme
- Saiote, Joana
- Ramos, Jaime
Other Objects (12)
Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis
Tofacitinib in treatment-refractory moderate to severe ulcerative colitis: real-world experience from a retrospective multicenter observational study
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis
Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
Severe ulcerative colitis induced by COVID-19 vaccination
Severe de novo Ulcerative Colitis following Ixekizumab Therapy
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon
Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis
Tofacitinib in treatment-refractory moderate to severe ulcerative colitis: real-world experience from a retrospective multicenter observational study
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis
Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
Severe ulcerative colitis induced by COVID-19 vaccination
Severe de novo Ulcerative Colitis following Ixekizumab Therapy
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon
Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis
Tofacitinib in treatment-refractory moderate to severe ulcerative colitis: real-world experience from a retrospective multicenter observational study
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis
Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
Severe ulcerative colitis induced by COVID-19 vaccination
Severe de novo Ulcerative Colitis following Ixekizumab Therapy
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon